243PD - OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice
| Autor: | Delaloge, S., Conte, P.F., Im, S-A., Senkus-Konefka, E., Xu, B., Domchek, S.M., Masuda, N., Li, W., Tung, N., Armstrong, A., Wu, W., Goessl, C., Runswick, S., Robson, M. |
|---|---|
| Zdroj: | In Annals of Oncology September 2017 28 Supplement 5:v77-v77 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|